Plain-English translation of NCT05039619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help teenagers (ages 12–17) and younger children (ages 5–11) whose lupus has caused serious inflammation in their kidneys. The medication is an antibody—a protein that helps the immune system fight the cells causing kidney damage. Researchers want to know whether this treatment is safe and whether it works better than a placebo (a dummy medication).
Lupus nephritis is a serious complication of lupus that damages the kidneys and can lead to long-term kidney problems or failure, especially in young patients. Current treatments don't work well enough for all children and teens, so researchers are testing whether this medication could be a better option.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the trial, you will receive either the new medication or a placebo through an IV (intravenous) infusion. You will come to the clinic five times over about one year to receive these infusions—on day 1, day 14, week 24, week 26, and week 52. You will also have regular blood and urine tests to monitor how the treatment is working and to check for any side effects. The trial will compare whether young people who receive the medication do better than those who receive placebo.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States